Finance

Lists
BSX:NYSE
Boston Scientific Corp
$43.10
-4.14%
(-1.86) 1D
$43.28
+0.42% (+0.18)
After hours
Closed: Sep 10, 4:00:05 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BSX...
Open
$44.13
High
$44.42
Low
$42.78
Mkt. cap
62.46B
Avg. vol.
20.50M
Volume
0.00
P/E ratio
17.48
52-wk high
$105.72
52-wk low
$42.20
EPS
$2.47
Beta
0.57
Shares outstanding
1.45B
No. of employees
59K
Open
$44.13
High
$44.42
Low
$42.78
Mkt. cap
62.46B
Avg. vol.
20.50M
Volume
0.00
P/E ratio
17.48
52-wk high
$105.72
52-wk low
$42.20
EPS
$2.47
Beta
0.57
Shares outstanding
1.45B
No. of employees
59K
News stories
From web sources and news partners
Profile
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
About Boston Scientific Corp
CEOMichael F. Mahoney
Employees59K
FoundedJun 29, 1979
HeadquartersMarlborough, Massachusetts, United States
SectorMedical device
Websitebostonscientific.com
Analyst ratings
Based on 22 analysts giving stock ratings to BSX in the past 3 months
Strong buy
Buy
20
Hold
2
Sell
0
12-month forecast
Based on 22 Wall Street analysts offering 12 month price targets for BSX in the last 3 months.
Highest
Current $43.10
$85.00 (+97.22%)
Average
$60.35 (+40.02%)
Lowest
$50.00 (+16.01%)
Analyst
Recommendation
Action
Price target
Projected
Date
Richard Newitter
Truist Financial
Buy
Maintained
-
-
09/09/2026
Marie Thibault
BTIG
Buy
Reiterated
$56.00
+29.9%
09/09/2026
Travis Steed
Bank of America Securities
Buy
Maintained
$54.00
+25.3%
09/08/2026
Joanne Wuensch
Citi
Buy
Maintained
$57.00
+32.3%
09/10/2026
Josh Jennings
TD Cowen
Buy
Maintained
$56.00
+29.9%
09/04/2026
Matthew Taylor
Jefferies
Buy
Reiterated
$60.00
+39.2%
08/21/2026
David Toung
Argus Research
Hold
Downgraded
-
-
07/30/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
$60.00
+39.2%
07/31/2026
Robbie Marcus
J.P. Morgan
Buy
Reiterated
$56.00
+29.9%
07/30/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$55.00
+27.6%
07/30/2026
Suraj Kalia
Oppenheimer
Buy
Maintained
$85.00
+97.2%
07/30/2026
Pito Chickering
Deutsche Bank
Buy
Maintained
$60.00
+39.2%
07/30/2026
David Rescott
Robert W. Baird
Buy
Maintained
$56.00
+29.9%
07/30/2026
William Plovanic
Canaccord Genuity
Buy
Reiterated
$66.00
+53.1%
07/30/2026
Kendall Au
RBC Capital
Buy
Reiterated
$70.00
+62.4%
07/29/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
$70.00
+62.4%
07/29/2026
Mike Kratky
Leerink Partners
Buy
Maintained
$60.00
+39.2%
07/30/2026
Larry Biegelsen
Wells Fargo
Hold
Maintained
$50.00
+16%
07/29/2026
Michael Matson
Needham
Buy
Maintained
$57.00
+32.3%
07/29/2026
Patrick Wood
UBS
Buy
Maintained
$67.00
+55.5%
07/30/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$60.00
+39.2%
07/29/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
$85.00
+97.2%
07/27/2026
David Roman
Goldman Sachs
Buy
Maintained
$57.00
+32.3%
07/14/2026
Matthew O'Brien
Piper Sandler
Buy
Maintained
$65.00
+50.8%
06/12/2026
Stephanie Elghazi
Bank of America Securities
Buy
Maintained
$68.00
+57.8%
06/09/2026
Michael Polark
Wolfe Research
Hold
Downgraded
-
-
05/29/2026
Matt Miksic
Barclays
Buy
Maintained
$89.00
+106.5%
05/28/2026
Christopher Pasquale
Nephron
Buy
Upgraded
$85.00
+97.2%
04/23/2026
Hans Engel
Erste Group
Hold
Reiterated
-
-
04/01/2026
Jayson Bedford
Raymond James
Buy
Maintained
$88.00
+104.2%
03/27/2026
Danielle Antalffy
UBS
Buy
Reiterated
$105.00
+143.6%
03/17/2026
Lee Hambright
Bernstein
Buy
Maintained
$112.00
+159.9%
02/05/2026
Last report
Jul 29, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.86 / $0.83
+3.86%beat
Revenue / Est. (USD)
5.44B / 5.37B
+1.42%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
5.06B
5.29B
5.20B
5.44B
Cost of goods sold
1.54B
1.61B
1.60B
1.61B
Cost of revenue
1.54B
1.61B
1.60B
1.61B
Research and development expenses
514.00M
569.00M
516.00M
554.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.74B
1.83B
1.78B
1.80B
Operating expense
2.48B
2.63B
2.53B
2.59B
Total operating expenses
4.02B
4.24B
4.13B
4.20B
Operating income
1.05B
1.04B
1.07B
1.25B
Other non operating income
-16.00M
28.00M
28.00M
-6.00M
EBT including unusual items
938.00M
700.00M
1.16B
1.06B
EBT excluding unusual items
935.00M
1.01B
999.00M
1.14B
Income tax expense
183.00M
30.00M
-176.00M
155.00M
Effective tax rate
19.51%
4.29%
-15.13%
14.62%
Other operating expenses
-
-
-
-
Net income
755.00M
672.00M
1.34B
907.00M
Net profit margin
14.91%
12.71%
25.77%
16.67%
Earnings per share
0.75
0.80
0.80
0.86
Interest and investment income
-
29.00M
-
11.00M
Interest expense
-87.00M
-90.00M
-90.00M
-96.00M
Net interest expenses
-87.00M
-61.00M
-90.00M
-85.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.39B
1.41B
1.42B
1.60B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps